Lilly’s Oral GLP-1 Just Hit Its Numbers. It’s Still Not Reversal.

Eli Lilly’s oral GLP-1, orforglipron, just hit its primary endpoint in the first Phase 3 trial designed to support an FDA submission. The Lilly press release announced results from ACHIEVE-1, published in The New England Journal of Medicine, showing a 1.3%–1.6% A1c reduction and 6.8%–7.9% weight loss in adults with early Type 2 diabetes on diet and exercise alone. For the 38 million Americans living with Type 2 diabetes, this is being framed as the moment a pill replaces the injection. It is — for managing the disease. It is not, and cannot be, a reversal.

What Just Happened

The Lilly press release announced that ACHIEVE-1, the first Phase 3 trial of orforglipron designed to support an FDA submission, met its primary endpoint and all key secondary endpoints. The trial enrolled adults with early Type 2 diabetes inadequately controlled on diet and exercise alone (baseline HbA1c ~7.0%, insulin- naïve), randomized to once-daily orforglipron (3 mg, 12 mg, or 36 mg) versus placebo for 40 weeks.

The headline numbers from the NEJM publication and Fierce Pharma’s coverage:

  • HbA1c reduction at 40 weeks: −1.3% (3 mg), −1.5% (12 mg), −1.6% (36 mg) versus −0.4% placebo — treatment differences of −0.9% to −1.2% versus placebo, all p < 0.001, per the NEJM publication.
  • Weight loss at 40 weeks: −6.8% (3 mg), −7.5% (12 mg), −7.9% (36 mg) versus −1.5% placebo, per the Lilly press release.
  • Clinical meaning: A ~1.5% absolute A1c drop in early-diabetes patients moves many from the high-7 into the low-6% range — a meaningful effect for a single oral agent, as noted in Fierce Pharma’s analysis.
  • Safety profile: Predominantly mild-to-moderate GI effects (nausea, diarrhea, vomiting) consistent with the GLP-1 class; discontinuation due to adverse events 6–8% versus 1% placebo, per the NEJM publication.
  • FDA submission timeline: Lilly expects to submit orforglipron to the FDA for weight management by year-end 2026 and for Type 2 diabetes in 2027, per the press release.

The Question Nobody’s Asking

Here’s what every headline about orforglipron is leaving out: this drug still manages diabetes. It does not reverse it.

Orforglipron works by mimicking a single gut hormone — GLP-1 — that tells your pancreas to make more insulin, slows your stomach emptying, and quiets your hunger signals. You take it once a day. When you stop, the A1c comes back. The weight comes back. The medication never addresses why your blood sugar was dysregulated in the first place — it overrides the symptom while the underlying insulin resistance keeps running the show.

That’s not a flaw. That’s pharmacology. Every GLP-1 on the market — injectable or oral — is a lifelong lease on disease management, not a deed to remission. A 1.5% A1c drop is a real win for patients who need medication. But “more convenient diabetes management” and “reversal of Type 2 diabetes” are two completely different games.

So the real question for the millions of Americans being told a pill will replace their injection isn’t “which GLP-1 pill should I take?” It’s “why am I still diabetic in the first place, and what’s actually required to reverse it?”

What Reversal Actually Looks Like

At Diabetes Reversal Group, we measure reversal by a single, unblinking standard: A1c 6.4% or lower — off every diabetes medication — sustained. Not “controlled.” Not “managed.” Reversed.

Our patients hit reversal in an average of 4.5 months — the time to get the attached results, within the 4.5- month average from the independent study. The mechanism isn’t a molecule. It’s a system: a patented nutrition protocol (240 recipes, 7-day meal plans, telemedicine delivery, mobile app coaching) that reverses the underlying insulin resistance at the root. The world’s only patented protocol for Type 2 diabetes reversal (U.S. patent granted September 2020), validated by an independent study of 137 participants (2013–2021) showing an average post-program A1c of 6.04%.

The Bottom Line

An oral GLP-1 that drops A1c by 1.5 points is a real win for patients who need medication. A system that reverses the disease is a different game entirely — one the pharmaceutical pipeline cannot build.

By: Dr. Jeffrey Hockings / Co-Founder/CEO / Diabetes Reversal Group
Kristine Burke, MD / Chief Medical Officer / Diabetes Reversal Group.

The only patented system in the world proven to reverse Type 2 diabetes.